Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Account Payables: 2020-2024

Historic Change in Account Payables for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $1.6 million.

  • Janux Therapeutics' Change in Account Payables fell 114.30% to -$168,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $867,000, marking a year-over-year increase of 146.31%. This contributed to the annual value of $1.6 million for FY2024, which is 471.84% up from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' Change in Account Payables is $1.6 million, which was up 471.84% from $277,000 recorded in FY2023.
  • Over the past 5 years, Janux Therapeutics' Change in Account Payables peaked at $2.1 million during FY2021, and registered a low of -$294,000 during FY2022.
  • For the 3-year period, Janux Therapeutics' Change in Account Payables averaged around $522,333, with its median value being $277,000 (2023).
  • Per our database at Business Quant, Janux Therapeutics' Change in Account Payables spiked by 15,178.57% in 2021 and then plummeted by 113.74% in 2022.
  • Yearly analysis of 5 years shows Janux Therapeutics' Change in Account Payables stood at $14,000 in 2020, then soared by 15,178.57% to $2.1 million in 2021, then tumbled by 113.74% to -$294,000 in 2022, then surged by 194.22% to $277,000 in 2023, then spiked by 471.84% to $1.6 million in 2024.